Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate to severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Eligible Conditions
- Psychosis, Involutional
- Anhedonia
Treatment Effectiveness
Effectiveness Progress
This is further along than 85% of similar trials
Other trials for Psychosis, Involutional
Study Objectives
1 Primary · 9 Secondary · Reporting Duration: Baseline up to Day 57
Baseline to Day 43
Change From Baseline in Dimensional Anhedonia Rating Scale (DARS) Total Score to Day 43
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Day 43
Change From Baseline in Patient Health Questionnaire, 9-item (PHQ-9) Total Score to Day 43
Percentage of Responders on Depressive Symptoms Scale from Baseline to Day 43 as Assessed by MADRS Total Score
Day 57
Change From Baseline Over Time in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form - Ability to Participate in Social Roles and Activities 8a (PROMIS-APS 8a)
Change From Baseline in DARS Total Score Over Time
Change From Baseline in MADRS Total Score over Time
Change from Baseline in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1) Over Time
Day 43
Percentage of Participants With Remission of Depressive Symptoms at Day 43 as Assessed by MADRS Total Score
Percentage of Participants With a Score Less than (<) 2 in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1) at Day 43
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Other trials for Psychosis, Involutional
Trial Design
2 Treatment Groups
Aticaprant
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
830 Total Participants · 2 Treatment Groups
Primary Treatment: Aticaprant · Has Placebo Group · Phase 3
Aticaprant
Drug
Experimental Group · 1 Intervention: Aticaprant · Intervention Types: DrugPlacebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: OtherTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline up to day 57
Closest Location: University of Alabama at Birmingham · Birmingham, AL
1991First Recorded Clinical Trial
0 TrialsResearching Psychosis, Involutional
1066 CompletedClinical Trials
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have a history of major depression and must not demonstrate a clinically significant improvement (that is, an improvement of more than 20 percent [%] on their HDRS-17 total score) between the first and the second independent HDRS-17 assessments.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments